SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

Study acronym: SACTION01
StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from May 31, 2026 to May 31, 2029
    • Eligibility criteria expanded, about 43 words
    • Publications: details revised at 1 of 1 entry
  2. Study completion date: Apr 2025 to May 31, 2026v5
  3. Study title revised
    • Eligibility criteria expanded, about 1 word
    v4
  4. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Apr 2024 to Jun 25, 2023
    • Study completion date: Apr 2024 to Apr 2025
    • Site details revised
    v3
  5. Start date changed from estimate of Apr 2022 to Apr 24, 2022v2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out the effectiveness stereotactic body radiation therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as treatment for operable stage II to III non-small cell lung cancer (NSCLC) prior to surgery.
Trial Details
NCT Number NCT05319574
Lead Sponsor Sun Yat-sen University
Conditions
(from sponsor)		 Carcinoma, Non-Small-Cell Lung
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 46 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov